Praxis Precision Medicines receives UBS buy rating with $706 target price
PRAX•UBS initiated coverage of Praxis Precision Medicines with a buy rating and a $706 target price.
Related News
Nasdaq halts trading in MF at 10:32 a.m. for volatility
MF•
Dollar retreats from 18-month high despite strong inflation data
TLT•
JLL arranges sale of Dallas Bishop Arts mixed-use portfolio to Hines
JLL•
Deckers Outdoor Corporation: UBS cuts target price to $140 from $161
DECK•
US business inventories rise moderately in August
SPY•